Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2Rb wild-type and knock-down in breast cancer cell lines

Fig. 3

Concurrent administration of Rib and Eve induced cytotoxicity in Rb WT and KD MCF-7 cells.Cell viability was determined by MTT assay. a Rb WT and b KD MCF-7 cells were treated with a concurrent dosing schedule with different concentrations (5, 10 and 20 μg/mL). Data shown are expressed as mean ± SE of three separate experiments. *p < 0.05 Rib/Eve- vs Rib-treated; #p < 0.05 Rib/Eve- vs Eve-treated

Back to article page